MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
Chemistry World
January 5, 2007
Victoria Gill
PEG Makes Cheaper Drugs for Developing Countries UK and Indian scientists have embarked on a collaboration to develop a new protein-based treatment for hepatitis C, which they say will provide an affordable drug urgently needed in countries where resources are limited. mark for My Articles similar articles
BusinessWeek
November 24, 2003
John Carey
Barring The Door Against AIDS A new generation of drugs focuses on keeping the virus from entering cells. mark for My Articles similar articles
The Motley Fool
August 10, 2010
Ryan McBride
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. mark for My Articles similar articles
Chemistry World
June 2008
Sarah Houlton
Breaking the rules The author finds out about some chemical tricks that can give a new drug the best possible odds of success mark for My Articles similar articles
The Motley Fool
March 31, 2011
Brian Orelli
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? mark for My Articles similar articles
The Motley Fool
September 8, 2010
Brian Orelli
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. mark for My Articles similar articles
Chemistry World
November 2, 2009
Simon Hadlington
New way to find drugs' unintended targets Researchers in the US have devised a new way to predict 'off-target' effects for pharmaceutical drugs. mark for My Articles similar articles
The Motley Fool
July 27, 2011
Brian Orelli
Good Combo; Too Bad There's Competition Vertex's VX-222 helps standard of care but still requires an injected medication. mark for My Articles similar articles
Chemistry World
November 25, 2008
James Urquhart
Virus revealed by flipping lipid A drug that flags up virus-infected cells for destruction by the body's own immune system could lead to new, broad-spectrum anti-viral treatments, say US scientists. mark for My Articles similar articles
The Motley Fool
October 31, 2011
Brian Orelli
Gunning for the Leaders Hepatitis C drugs take center stage. mark for My Articles similar articles
HHMI Bulletin
May 2010
Sarah C.P. Williams
Lab-Grown Liver New cell culture system solves problem of growing liver cells. mark for My Articles similar articles
Chemistry World
December 9, 2009
Sarah Houlton
New hep C breakthrough A drug being developed by Denmark's Santaris Pharma could provide a breakthrough in the treatment of hepatitis C, and positive results in a study on chimpanzees point to its potential to avoid drug resistance. mark for My Articles similar articles
The Motley Fool
April 17, 2008
Brian Lawler
The End for (Another) Hepatitis C Drug Candidate ViroPharma stops development of its compound after data showed it may hurt the liver. mark for My Articles similar articles
The Motley Fool
October 19, 2007
Brian Lawler
Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down. mark for My Articles similar articles
Chemistry World
September 1, 2008
James Mitchell Crow
Drug discovery on a chip Scientists in the US have, for the first time, used microfluidics to discover drug leads. The team's lab-on-a-chip device revealed inhibitors of a key membrane-bound protein in hepatitis C virus mark for My Articles similar articles
Nurse Practitioner
December 2009
Gujral & Collantes
Understanding Viral Hepatitis: A guide for primary care Recent advancements in the field of genomics and proteomics technology have given researchers and clinicians more insight on disease pathogenesis and helped create more tailored approaches to the treatment of these conditions. mark for My Articles similar articles
The Motley Fool
December 16, 2011
Brian Orelli
Safety (Still) Trumps Acquisitions in Hep C Pharmasset announced it was discontinuing all treatment arms in one of its phase 2b trials that contain the drug PSI-938. The drug candidate caused laboratory abnormalities in tests associated with liver function. mark for My Articles similar articles
Chemistry World
April 21, 2010
Sarah Houlton
Fresh hep C hope A new kind of compound to treat hepatitis C is showing promise in early clinical trials. mark for My Articles similar articles
American Family Physician
June 15, 2006
Brundage & Fitzpatrick
Hepatitis A The introduction of hepatitis A vaccines in 1995 led to a drop in the number of reported cases of hepatitis A and a shift to a higher percentage of cases occurring in older age groups. The hepatitis A virus survives for extended periods in the environment. mark for My Articles similar articles
American Family Physician
November 1, 2001
Thomas R. Riley
Preventive Strategies in Chronic Liver Disease Chronic liver disease is the 10th leading cause of death in the United States. Preventive care can significantly reduce the progression of liver disease. Part I: Alcohol, Vaccines, Toxic Medications and Supplements, Diet and Exercise... mark for My Articles similar articles
The Motley Fool
April 26, 2011
Brian Orelli
There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost. mark for My Articles similar articles
The Motley Fool
March 28, 2008
Brian Orelli
The Yin and Yang of Schering's Label Changes Schering gets a pair of label changes that have opposite effects for its hepatitis C drug. mark for My Articles similar articles
American Family Physician
January 1, 2004
Lin & Kirchner
Hepatitis B Hepatitis B causes significant morbidity and mortality worldwide. Effective vaccines for hepatitis B virus have been available since 1982; infant and childhood vaccination programs introduced in the 1990s have resulted in a marked decrease in new infections. mark for My Articles similar articles
American Family Physician
January 1, 2004
Hepatitis B Infection What is hepatitis B virus?... How can I tell if I have HBV infection?... What happens after HBV infection?... What health problems can chronic HBV infection cause?... How can I protect my liver if I have chronic HBV infection?... How can HBV infection be prevented?... etc. mark for My Articles similar articles
Chemistry World
June 12, 2014
Philli Broadwith
Merck & Co bolsters hepatitis C pipeline with Idenix acquisition US drug firm Merck & Co has agreed to buy hepatitis C specialist Idenix for $3.85 billion. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2005
Ron Feemster
The PharmExec 2005 Pipeline Report Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and -- at last -- innovative mechanisms for troublesome targets: Acomplia [rimonabant] by Sanofi-Aventis... AMG 162 [denosumab] by Amgen... etc. mark for My Articles similar articles
The Motley Fool
August 10, 2007
Brian Lawler
ViroPharma Whacked by Data Shares of ViroPharma fall after safety issues come to light with one of its drugs. A phase 2 study of their hepatitis C antiviral medication has been halted, with only a slim chance of starting up again. mark for My Articles similar articles
Chemistry World
April 2009
Derek Lowe
Column: In the pipeline The author considers the problems of addressing drug development out of sequence mark for My Articles similar articles
Chemistry World
July 26, 2012
Derek Lowe
Screen shots You might not think that the makeup of a compound screening collection could set off many arguments, but there are a few issues there that will do the trick almost every time. mark for My Articles similar articles
The Motley Fool
May 28, 2010
Brian Orelli
Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree. mark for My Articles similar articles
Chemistry World
November 2009
Derek Lowe
Column: In the pipeline The author advises opening your mind during the screening cascade taken by potential drug targets, and remaining goal orientated at all times mark for My Articles similar articles
The Motley Fool
July 7, 2011
Brian Orelli
J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo. mark for My Articles similar articles
The Motley Fool
June 27, 2008
Brian Lawler
Difficult Obstacles for SciClone With all the new technologies and discoveries, some drugmakers are undoubtedly going to be left in the dust. SciClone Pharmaceuticals, with its lead drug Zadaxin, might be one such drugmaker. mark for My Articles similar articles
Chemistry World
October 2008
Derek Lowe
Column: In the pipeline The author seeks a cure for 'compound bloat' mark for My Articles similar articles
Chemistry World
October 31, 2008
Matt Wilkinson
GSK Snaps up Hepatitis Drug Developer In a bid to strengthen its efforts to develop new hepatitis therapies, GSK has agreed to buy Genelabs Technologies in a deal worth $57 million. mark for My Articles similar articles
The Motley Fool
January 30, 2009
Brian Orelli
Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients. mark for My Articles similar articles
The Motley Fool
September 27, 2005
Jack Uldrich
A Ray of Hope for Flamel? New hepatitis C treatment offers a ray of hope to the ailing nanotech company. Unfortunately, this news does not guarantee sunnier days ahead. mark for My Articles similar articles
The Motley Fool
April 19, 2004
Charly Travers
4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry. mark for My Articles similar articles
The Motley Fool
April 29, 2008
Brian Lawler
So Pharmasset, So Good Early data hints at a promising hepatitis C treatment. mark for My Articles similar articles
Reactive Reports
Issue 41
David Bradley
Chip Chops Time off Drug Discovery Process A next-generation optical screening platform can screen a vast number of compounds rapidly by passing wave after wave of compounds in solution over the surface of the biochip. mark for My Articles similar articles
The Motley Fool
January 9, 2012
Travis Hoium
Idenix Pharmaceuticals Shares Jumped: What You Need to Know Shares of Idenix Pharmaceuticals got a positive diagnosis today and climbed 43% after the company released positive data for its hepatitis C drug. mark for My Articles similar articles
The Motley Fool
May 15, 2008
Brian Lawler
What's Cooking at Flamel? The drugmaker makes finding partners to help pay for its hepatitis C and diabetes compounds a top priority. mark for My Articles similar articles
Pharmaceutical Executive
February 1, 2006
Ron Feemster
Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets. mark for My Articles similar articles
The Motley Fool
June 14, 2011
Brian Orelli
Going for Seconds in the Hepatitis C Space Fresh from the Food and Drug Administration's approval of its hepatitis C drug, Incivek, Vertex has licensed a pair of hepatitis C compounds from privately held Alios BioPharma. mark for My Articles similar articles
The Motley Fool
March 4, 2009
Brian Orelli
Vertex Combines to Keep From Being Ground Up Vertex Pharmaceuticals announces that it is buying ViroChem Pharma, getting two early stage hepatitis C compounds in the deal. mark for My Articles similar articles
Chemistry World
April 2011
Column: In the Pipeline If you look over the whole pharmacopeia, you'll see there are a lot of compounds that got their start as natural products. mark for My Articles similar articles
Chemistry World
December 2008
Column: In the pipeline I've worked on two drug discovery efforts (one right after the other, as fate would have it) whose final compounds differed by essentially one methyl group from the starting points of each project. mark for My Articles similar articles
Chemistry World
September 16, 2008
Hepeng Jia
Research Initiative Targets China's Major Killer Diseases A new epidemics research initiative is targeting China's biggest killer diseases: HIV/AIDS, tuberculosis (TB) and virulent hepatitis. mark for My Articles similar articles
American Family Physician
June 15, 2006
Hepatitis A: What You Should Know A patient guide: What is hepatitis A?... How is the disease spread?... How can I tell if I have the disease?... How is this disease treated?... How long will I be contagious?... etc. mark for My Articles similar articles
Chemistry World
June 2011
Column: In the pipeline Chemists are human. Humans are hierarchical. Therefore...well, therefore, you'll find a number of different roles and levels for scientists in a drug company's labs. Here's a rough ordering, from least experienced to most. mark for My Articles similar articles